Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. EYPT
EYPT logo

EYPT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy EyePoint Inc (EYPT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
13.580
1 Day change
3.27%
52 Week Range
19.110
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

EYPT is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is technically weak, there is no recent news catalyst, no strong proprietary buy signal, and option sentiment is mixed-to-bearish. I would not buy here based on the current data.

Technical Analysis

Current price is 12.505, essentially flat versus the prior close, with the market overall up strongly. Momentum is weak: MACD histogram is below zero and still contracting, RSI_6 is neutral at 54.3, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Price is sitting just under the pivot level of 12.561, with support at 11.52 and resistance at 13.602. The short-term pattern data suggests limited downside in the next day but a weak next-week outlook, making this a poor immediate entry for a long-term beginner.

Options Data

Neutral
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options positioning is mixed. The open interest put-call ratio at 1.05 is slightly bearish, showing more put positioning than calls by open interest. However, the option volume put-call ratio at 0.09 is strongly call-skewed for today's activity, suggesting near-term traders were buying calls. Implied volatility is elevated at 91.41, with IV percentile 67.33 and IV rank 31.41, which signals relatively expensive options pricing. Overall options sentiment is not a clean bullish confirmation.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
9

Positive Catalysts

  • No news in the recent week means there is no obvious event-driven catalyst. The only mildly positive element is that options volume skewed heavily toward calls today, which may reflect speculative short-term optimism. Stock trend modeling also suggests a possible 3.65% gain over the next month, but this is not strong enough to outweigh the weak technical setup.

Neutral/Negative Catalysts

  • There are no recent news catalysts, no AI Stock Pick signal, and no recent SwingMax signal. Hedge funds and insiders are both neutral, offering no accumulation signal. Technicals are bearish, with MACD below zero and declining, and the moving average structure remains weak. Open interest is slightly put-heavy, implying cautious sentiment. The stock also appears to be trading below a key pivot level with only modest nearby support.

Financial Performance

No usable latest-quarter financial snapshot was provided, so I cannot confirm revenue or earnings growth trends. The latest quarter season is not available from the supplied data. Because of that, there is no financial growth evidence here to support an immediate long-term buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no visible Wall Street upgrade/downgrade trend to summarize. Based on the available evidence, Wall Street appears neutral at best: no strong bullish analyst catalyst, no insider accumulation, and no hedge fund buying trend. The pros view is limited by the lack of positive rating momentum; the cons view is supported by weak technicals, absent news catalysts, and mixed options sentiment.

Wall Street analysts forecast EYPT stock price to rise
6 Analyst Rating
Wall Street analysts forecast EYPT stock price to rise
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.150
sliders
Low
20
Averages
31.5
High
43
Current: 13.150
sliders
Low
20
Averages
31.5
High
43
Citi
Buy
upgrade
$31 -> $35
AI Analysis
2026-03-09
Reason
Citi
Price Target
$31 -> $35
AI Analysis
2026-03-09
upgrade
Buy
Reason
Citi raised the firm's price target on EyePoint to $35 from $31 and keeps a Buy rating on the shares.
H.C. Wainwright
Yi Chen
maintain
$23 -> $30
2026-03-05
Reason
H.C. Wainwright
Yi Chen
Price Target
$23 -> $30
2026-03-05
maintain
Reason
H.C. Wainwright analyst Yi Chen raised the firm's price target on EyePoint to $30 from $23 and keeps a Buy rating on the shares following the Q4 report. The firm included the company's Phase 3 diabetic macular edema program into the stock's valuation.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for EYPT
Unlock Now

People Also Watch